Design Therapeutics Inc (DSGN)
3.71
-0.11
(-2.88%)
USD |
NASDAQ |
Jun 14, 16:00
3.71
0.00 (0.00%)
Pre-Market: 20:00
Design Therapeutics Enterprise Value: -61.09M for June 14, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 14, 2024 | -61.09M |
| June 13, 2024 | -54.88M |
| June 12, 2024 | -57.70M |
| June 11, 2024 | -43.01M |
| June 10, 2024 | -56.00M |
| June 07, 2024 | -53.18M |
| June 06, 2024 | -39.62M |
| June 05, 2024 | -35.67M |
| June 04, 2024 | -41.32M |
| June 03, 2024 | -40.75M |
| May 31, 2024 | -41.88M |
| May 30, 2024 | -48.10M |
| May 29, 2024 | -53.18M |
| May 28, 2024 | -32.84M |
| May 24, 2024 | -24.37M |
| May 23, 2024 | -43.01M |
| May 22, 2024 | -35.67M |
| May 21, 2024 | -36.80M |
| May 20, 2024 | -22.11M |
| May 17, 2024 | -21.54M |
| May 16, 2024 | -16.46M |
| May 15, 2024 | -15.89M |
| May 14, 2024 | -17.02M |
| May 13, 2024 | -13.63M |
| May 10, 2024 | -12.50M |
| Date | Value |
|---|---|
| May 09, 2024 | -1.205M |
| May 08, 2024 | -5.724M |
| May 07, 2024 | -5.724M |
| May 06, 2024 | -64.48M |
| May 03, 2024 | -60.52M |
| May 02, 2024 | -64.48M |
| May 01, 2024 | -66.17M |
| April 30, 2024 | -71.82M |
| April 29, 2024 | -60.52M |
| April 26, 2024 | -57.13M |
| April 25, 2024 | -58.26M |
| April 24, 2024 | -64.48M |
| April 23, 2024 | -63.91M |
| April 22, 2024 | -50.92M |
| April 19, 2024 | -61.65M |
| April 18, 2024 | -59.39M |
| April 17, 2024 | -48.10M |
| April 16, 2024 | -62.22M |
| April 15, 2024 | -56.57M |
| April 12, 2024 | -62.22M |
| April 11, 2024 | -57.70M |
| April 10, 2024 | -56.01M |
| April 09, 2024 | -59.96M |
| April 08, 2024 | -58.27M |
| April 05, 2024 | -58.27M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-188.32M
Minimum
Aug 21 2023
2.197B
Maximum
Mar 26 2021
306.08M
Average
316.72M
Median
Jan 31 2022
Enterprise Value Benchmarks
| Biogen Inc | 39.20B |
| AbbVie Inc | 353.68B |
| PTC Therapeutics Inc | 2.146B |
| Revance Therapeutics Inc | 447.31M |
| Context Therapeutics Inc | 136.91M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -11.10M |
| Total Expenses (Quarterly) | 14.40M |
| EPS Diluted (Quarterly) | -0.20 |
| Earnings Yield | -28.30% |